{"filings":[{"id":746881,"accession_number":"0001628280-26-039189","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-05-29T20:14:42+00:00","items":["5.07"],"status":"ready","headline":"Castle Biosciences stockholders elect three Class I directors and ratify KPMG as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson elected as Class I directors to serve until 2029 annual meeting.","KPMG LLP ratified as independent auditor for FY 2026 with 24,531,366 for, 445,666 against, 12,187 abstain.","Advisory vote on named executive officer compensation approved: 21,280,180 for, 1,281,394 against, 11,857 abstain.","Non-employee director compensation policy approved: 21,394,330 for, 1,130,133 against, 48,968 abstain.","All four proposals passed with requisite votes; broker non-votes of 2,415,788 on director elections and advisory/compensation items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92918,"accession_number":"0001628280-26-031255","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).","Net loss improved to $14.5M ($0.49/share) from $25.8M ($0.90); adjusted EBITDA -$5.1M vs +$13.0M.","Raises FY2026 revenue guidance to $345-355M from $340-350M; cash & investments $261.7M.","Gross margin 73% (adj. 76%) vs 49% (adj. 81%) prior year, which included $20.1M amortization acceleration.","Operating cash use $22.1M includes $28.8M in one-time bonus/benefit payments not expected to recur in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":83679000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104149,"accession_number":"0001628280-26-012263","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.","Q4 revenue $87.0M (+1%); core reports +42%. TissueCypher reports up 86% in FY2025.","Net loss $24.2M ($0.83 loss per share) vs net income $18.2M ($0.66 EPS) in 2024. Adj. net loss per share $0.14.","Adjusted EBITDA $44.0M (FY2025) vs $75.0M (2024); net cash from ops $64.3M; cash & securities $299.5M at year-end.","2026 revenue guidance $340-350M; AdvanceAD-Tx limited launch; multiple publications support test utility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":344229000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104148,"accession_number":"0001628280-26-001909","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2025 total revenue >$340M, above guided range of $327-335M.","Q4 core test reports (DecisionDx-Melanoma, TissueCypher) +42% YoY.","DecisionDx-Melanoma Q4: 10,022 reports; TissueCypher Q4: 11,803 reports.","Year-end cash + marketable securities ~$300M.","AdvanceAD-Tx launched Nov 2025; >50% of initial clinicians ordered in first 5 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":344229000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120416,"accession_number":"0001628280-25-048248","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.","Total test reports 26,841; DecisionDx-Melanoma and TissueCypher each exceeded 10,000 tests in a quarter for first time.","Full-year 2025 revenue guidance raised to $327-335M from $310-320M.","Launched AdvanceAD-Tx, a GEP test to guide systemic treatment for moderate-to-severe atopic dermatitis.","Non-dermatologic revenue up 67% YoY; adjusted EBITDA $9.2M vs $21.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":257219000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136996,"accession_number":"0001447362-25-000099","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Castle Biosciences adopts amended bylaws with changes to meeting procedures and governance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted amended and restated bylaws effective August 5, 2025, modifying quorum, advance notice, and proxy rules.","Advance notice window for stockholder proposals widened: meeting delayed >70 days (previously 30) triggers alternative deadline.","Quorum changed from majority of outstanding shares to majority of voting power; default approval threshold now majority of votes cast.","Universal proxy rules under Rule 14a-19 incorporated; stockholder nominees limited to number of directors to be elected.","Indemnification obligations expanded to maximum extent allowed by law; mandatory advancement of expenses clarified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136995,"accession_number":"0001447362-25-000096","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.","TissueCypher test reports nearly doubled to 9,170 (from 4,782); DecisionDx-Melanoma up 4% to 9,981.","Raising FY2025 total revenue guidance to $310-320M from $287-297M, citing strong core test performance.","Net income $4.5M ($0.16 diluted EPS) vs $8.9M ($0.32) YoY; adjusted EBITDA $10.4M vs $21.5M.","FDA Breakthrough Device designation for DecisionDx-Melanoma; closed Previse acquisition and SciBase collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":174176000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154276,"accession_number":"0001447362-25-000085","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Castle Biosciences shareholders approve officer exculpation charter amendment; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to certificate of incorporation to limit officer liability per Delaware law, effective May 22, 2025.","Re-elected Class III directors Kimberlee S. Caple, G. Bradley Cole, and Derek J. Maetzold to terms expiring 2028.","Ratified KPMG as independent auditor for FY2025 with 23.7M votes for, 20.8K against.","Approved advisory say-on-pay proposal with 20.0M for, 1.3M against, 43K abstain.","All proposals passed with overwhelming support; broker non-votes noted for director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154275,"accession_number":"0001447362-25-000068","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.","Net loss $(0.90) per share incl. $20.1M amortization acceleration; adjusted net loss $(0.20); Adj. EBITDA $13.0M.","FY 2025 revenue guidance raised to $287-297M from prior $280-295M.","Signed definitive agreement to acquire Previse, a GI health company focused on esophageal cancer; no terms disclosed.","DecisionDx-Melanoma surpassed 200,000 test orders; IDgenetix test to be discontinued effective May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":87988000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172862,"accession_number":"0001447362-25-000030","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).","Net income $18.2M (incl. $50.3M stock comp) vs net loss $57.5M in 2023.","Adjusted EBITDA $75.0M vs -$4.4M in 2023; cash $293.1M, up $50M.","TissueCypher Barrett's Esophagus test reports surged 130% to 20,956; dermatology reports up 17%.","2025 revenue guidance $280-295M, below 2024 actual but achieved prior 2025 target a year early."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":332069000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172861,"accession_number":"0001447362-25-000012","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.","Delivered 96,071 total test reports in 2024, up 36% YoY; TissueCypher Barrett's Esophagus test grew 130%.","Year-end 2024 cash, cash equivalents and marketable securities approximately $293M.","Medicare contractor Novitas finalized non-coverage for DecisionDx-SCC test on January 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":332069000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189869,"accession_number":"0001447362-24-000168","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.","Total test reports 26,010 (+41% YoY); TissueCypher up 115%, IDgenetix up 81%, DecisionDx-SCC up 49%.","Raises full-year 2024 revenue guidance to $320-330M from prior $275-300M.","Cash, equivalents and marketable securities $279.8M at Sept 30, 2024.","Q3 operating cash flow $23.3M vs $5.0M prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":245758000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206382,"accession_number":"0001447362-24-000121","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.","Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.","Raises FY2024 revenue guidance to $275-300M from prior $255-265M.","Adjusted EBITDA $21.5M vs ($5.3M) in Q2 2023; gross margin 81%.","Cash and investments $259.7M; net cash from operations $24.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":159976000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223500,"accession_number":"0001447362-24-000072","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Castle Biosciences stockholders elect directors, ratify KPMG, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel M. Bradbury elected as Class II director with 15.95M for, 5.28M withhold; Rodney Cotton with 21.11M for, 117K withhold.","Ratification of KPMG as independent auditor for FY2024: 22.27M for, 184K against, 17K abstain.","Advisory vote on executive compensation approved: 20.62M for, 306K against, 299K abstain, 1.24M broker non-votes.","Annual meeting held on May 23, 2024; all three proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223499,"accession_number":"0001447362-24-000059","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).","Net loss narrowed to $2.5M from $29.2M; adjusted EBITDA improved to $10.5M from -$15.1M.","Total test reports +40% to 20,888; TissueCypher +148%, IDgenetix +90%.","FY2024 revenue guidance raised to $255-265M from prior $235-240M.","Cash & marketable securities $239.2M; gross margin 78% (adj. 81%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":72974000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242946,"accession_number":"0001193125-24-078933","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Castle Biosciences secures $35M SVB loan facility; appoints Rodney Cotton to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Loan Agreement with Silicon Valley Bank for $10M drawn, $25M additional available.","Proceeds to fund future HQ office building and working capital; interest at WSJ Prime +0.25% (floor 6%).","Interest-only through Nov 2025 (extendable to Nov 2026); maturity Nov 2028; secured by most assets.","Director Mara Aspinall not standing for re-election; Rodney Cotton (ex-Roche) appointed as Class II director.","Cotton receives initial RSU valued at $350K vesting over 3 years plus annual $45K cash retainer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242945,"accession_number":"0001447362-24-000016","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).","Net loss $57.5M in 2023 vs. $67.1M in 2022; Q4 net loss $2.6M vs. $20.6M. Adjusted EBITDA $(4.4)M year, $9.4M Q4.","Cash, cash equivalents and marketable securities $243.1M at Dec 31, 2023.","TissueCypher test reports +328% YoY; DecisionDx-SCC +92%; IDgenetix +236%.","2024 revenue guidance: $235-240 million; management cites strong commercial momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":219788000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242944,"accession_number":"0001447362-24-000006","cik":1447362,"company_name":"CASTLE BIOSCIENCES INC","ticker":"CSTL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.","Delivered 70,429 total test reports in 2023, up 59% YoY; Q4 reports 20,284, up 60% YoY.","TissueCypher Barrett's Esophagus test reports surged 328% YoY in 2023; IDgenetix up 236%.","Year-end cash, equivalents and short-term investments expected ~$243M.","Preliminary results, subject to audit completion; final results may differ."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":219788000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":668775412.0202258,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}